Day: April 12, 2024

Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products

Written by Customer Service on April 12, 2024. Posted in Public Companies.

Signifies the first major step towards the application process for the certification of its Mango ED oral dissolvable products by Mexico’s health governing agency, COFEPRIS Dallas, Texas, April 12, 2024 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce that its subsidiary, MangoRx Mexico S.A. de C.V. (“MangoRx Mexico”), has secured and executed a technical agreement with Emifarma S.A. de C.V (“Emifarma”) for the initial stages of development and testing (Bioequivalence and Accelerated Stability, required to obtain registry from COFEPRIS) of the Company’s Mango ED products intended for...

Form 8.3 – [LOK’N STORE GROUP PLC – 11 04 2024] – (CGWL)

Written by Customer Service on April 12, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LOK’N STORE GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position...

Form 8.3 – [LOK’N STORE GROUP PLC – Opening Disclosure – 11 04 2024] – (CGAML)

Written by Customer Service on April 12, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary Clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LOK’N STORE GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

CSW Industrials Increases Quarterly Dividend by 10.5% to $0.21 Per Share

Written by Customer Service on April 12, 2024. Posted in Dividend Reports And Estimates.

DALLAS, April 12, 2024 (GLOBE NEWSWIRE) — The Board of Directors of CSW Industrials, Inc. (Nasdaq: CSWI) today declared a regular quarterly cash dividend of $0.21 per share. This represents an increase of $0.02 per share, or approximately 10.5%, as compared to the declared dividend in the prior quarter. The dividend is payable on May 10, 2024, to shareholders of record as of the close of business on April 26, 2024. “We are pleased to announce another increase in our quarterly dividend, reflecting our strong balance sheet, cash flows and profitability. Over the past five years, we have returned $143 million in cash to our shareholders through share repurchases and dividends, while delivering impressive growth, both organically and through acquisitions,” said Joseph B. Armes, CSW Industrials Chairman, President, and Chief Executive...

Notable Labs Reports 2023 Financial Results and Provides a Business Update

Written by Customer Service on April 12, 2024. Posted in Earnings Releases And Operating Results.

FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) — Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), reported financial results for the year ended December 31, 2023 and provided a business update. “The last year has been a time of great accomplishment for Notable. We built a strong clinical validation dataset, starting with a poster presented at the American Association for Cancer Research (AACR 2023); became a publicly listed company, following the closing of a reverse merger in October 2023; and reported successful PPMP clinical data from the Phase 2 fosciclopirox study that showcased the ability of our platform to accurately predict patient outcomes for specific therapeutics,”...

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Written by Customer Service on April 12, 2024. Posted in Earnings Releases And Operating Results.

In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a 90% reduction in their EASI score (EASI-90) after 16 weeks. 56% (5/9) of patients with prior inadequate response to dupilumab achieved EASI-90 and 56% (5/9) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks. Topline, unblinded data from the full dataset expected at the end of 2024. Phase 2 proof-of-concept trial of farudodstat in alopecia areata (the FAST-AA study) has recruited close to 75% of patients; topline data readout expected in Q3 2024. Positive opinion received from European Patent Office on new patent application of farudodstat with potential to extend protection until at least 2043.SAN MATEO, Calif. and SINGAPORE, April 12, 2024 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals...

Form 8.3 – [SPIRENT COMMUNICATIONS PLC – 11 04 2024] – (CGAML)

Written by Customer Service on April 12, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary Clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree SPIRENT COMMUNICATIONS PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Form 8.3 – [abrdn EUROPEAN LOGISTICS INCOME PLC – 11 04 2024] – (CGWL)

Written by Customer Service on April 12, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree abrdn EUROPEAN LOGISTICS INCOME PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Progressive Reports March 2024 Results

Written by Customer Service on April 12, 2024. Posted in Earnings Releases And Operating Results.

MAYFIELD VILLAGE, OHIO, April 12, 2024 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended March 31, 2024 and the first quarter of 2024: March Quarter (millions, except per share amounts and ratios; unaudited) 2024 2024 2023 ChangeNet premiums written $ 7,746.0 $ 18,962.2 $ 16,109.7 18 %Net premiums earned $ 5,633.5 $ 16,148.6 $ 13,533.1 19 %Net income $ 893.6 $ 2,331.4 $ 447.9 421 %Per share available to common shareholders $ 1.52 $ 3.94 $ 0.75 425 %Total pretax net realized gains (losses) on securities $ 58.3 $ 155.6 $ 71.8 117 %Combined ratio 84.3 86.1 99.0 (12.9) pts.Combined ratio – prior year month 106.2 Average diluted equivalent common shares 587.4 587.3 587.0 0 %In...

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

Written by Customer Service on April 12, 2024. Posted in Public Companies.

MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will participate in a fireside chat during the Emerging Growth Virtual Healthcare Equity Conference, presented by Noble Capital Markets, taking place from April 17 – 18, 2024. Details of the fireside chat are as follows: Date: Wednesday, April 17, 2024 Time: 10 a.m. ET Location: Presentation Track 1 Webcast: Available in the Events section of Ocugen website During the fireside chat and one-on-one sessions, Dr. Musunuri will showcase the Company’s recent business and clinical development progress including FDA clearance to initiate...

Day: April 12, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice